Regeneron Pharmaceuticals, Inc. Earnings Recaps
Regeneron's stock rose 9.7% following a Q2 report that delivered strong top-line growth led by blockbuster product sales, notably Dupixent and EYLEA HD, which outpaced expectations and reinforced confidence in the company’s commercial momentum and pipeline potential.
Key takeaways
- Total revenues grew 17% year-over-year, driven primarily by Dupixent’s global net sales of $6 billion, up 38% on a constant currency basis.
- EYLEA HD U.S. net sales nearly $600 million, up 52% year-over-year, with physician demand increasing 24% sequentially, marking the first quarter EYLEA HD sales surpassed the original EYLEA.
- Libtayo sales hit nearly $500 million globally, up 29% constant currency, supported by strong adoption in non-melanoma skin cancer and increased market share in non-small cell lung cancer (20% of new-to-brand U.S. prescriptions).
- Management highlighted a robust, diversified pipeline with promising early clinical data on follow-on Dupixent programs and next-generation interleukin-13 antibody candidates.
- Ongoing work with the FDA and partners targets year-end approval of a new EYLEA HD prefilled syringe, expected to further accelerate product adoption.
Regeneron shares fell 3.4% following the quarterly report, as the market responded negatively to regulatory delays affecting EYLEA HD and uncertainties around product supply. While financials showed top-line growth, investor focus shifted to unresolved FDA decisions and pending applications that cloud near-term visibility for a key franchise.
Key takeaways
- Total revenues grew 19% year-over-year, and non-GAAP EPS rose 15%, with broad-based commercial execution.
- Global DUPIXENT net sales increased 31% to $4.9 billion, and EYLEA HD U.S. net product sales grew 52% to $468 million; Libtayo sales advanced 54% to $438 million.
- Regulatory overhang persists: FDA did not act by the April PDUFA date on the second contract manufacturer for EYLEA HD prefilled syringes, and the application remains pending.
- Management anticipates a regulatory decision on EYLEA HD supply in the coming quarter, but timing remains uncertain.
- The Board approved a new $3 billion share repurchase program, signaling capital allocation discipline despite ongoing regulatory headwinds.
Regeneron Pharmaceuticals reported solid third quarter results for 2025, with robust sales growth driven by Dupixent and Libtayo, complemented by EYLEA HD achieving record revenue despite ongoing affordability challenges.
Key takeaways
- Dupixent generated $4.9 billion in global net sales, a 26% increase year-over-year, with dominance in multiple indications and growing patient base.
- Libtayo sales reached $365 million, up 24% year-over-year, bolstered by a recent FDA approval for use in high-risk adjuvant cutaneous squamous cell carcinoma.
- EYLEA HD sales hit an all-time high of $431 million in the U.S., driven by increased physician demand, though impacted by pricing pressures and market affordability issues.
- Ongoing regulatory challenges with prefilled syringe approvals for EYLEA HD could affect future growth potential; alternate filling plans set for submission by January 2026.
- Significant R&D progress announced with positive Phase III results across diverse therapeutic areas, enhancing pipeline momentum ahead of upcoming pivotal studies.